Track Zomedica Corp. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Zomedica Corp. ZOMDF · Stock Open Zomedica Corp. in new tab

0.0790 USD
EPS
-0.02
P/B
0.75
ROE
-16.29
Beta
1.33
Loading chart...
Key Metrics
EPS-0.02
Book Value0.11
Price to Book0.75
Debt/Equity1.71
% Insiders2.746%
Growth
Revenue Growth0.37%

DCF valuation

Model fair value for Zomedica Corp. (ZOMDF)
Result
Sign in to run the valuation for ZOMDF.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Zomedica Corp. Logo Zomedica Corp. Analysis (ZOMDF)

Is Zomedica Corp. a good investment? Zomedica Corp. (ZOMDF) is currently trading at 0.0790 USD.

Investor FAQ

Does Zomedica Corp. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Zomedica Corp.?

Zomedica Corp. is classified as a Stock.

Company Profile

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. It offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. The company provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, Assisi EquiLoop, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion